ArticleJournal of nanobiotechnology2026
Neutrophil membrane-mediated biomimetic nanoparticle for co-delivery of icariin and siORMDL3 attenuates asthma exacerbated by respiratory syncytial virus.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAsthma is a chronic inflammatory disorder, and respiratory syncytial virus (RSV) is a major trigger of asthma exacerbation. This study aimed to improve therapeutic efficacy against RSV-exacerbated asthma using neutrophil membrane (NM)-coated nanoparticles (NPs) for co-delivery of orosomucoid-like 3 (ORMDL3)-targeting small interfering RNA (siRNA) and icariin.
methodsA biomimetic dual-drug delivery system (ORMDL3-targeting siRNA [siORMDL3]/Icariin NPs@NM) was developed by coating NM onto poly(lactic-co-glycolic acid) NPs co-loaded with icariin and siORMDL3. The physicochemical properties, biosafety, cellular uptake, biodistribution behavior, and RNA interference efficiency of the NPs were evaluated. Their therapeutic efficacy was further assessed in vitro and in vivo.
resultsThe siORMDL3/Icariin NPs@NM exhibited a core-shell structure with NM camouflage, an average diameter of 141.1 nm, and a negatively charged surface. The NPs demonstrated enhanced lung-targeting delivery efficiency with no apparent adverse effects. In vitro, siORMDL3/Icariin NPs@NM significantly improved the viability of BEAS-2B cells treated with interleukin-4 and RSV, while markedly reducing inflammatory cytokine production and oxidative stress markers. In vivo, the siORMDL3/Icariin NPs@NM effectively alleviated airway resistance and improved the inflammatory microenvironment in mice with RSV-exacerbated asthma, with no observable toxicity in major organs.
conclusionsiORMDL3/Icariin NPs@NM demonstrated potent anti-inflammatory and antioxidative effects and may serve as an effective dual-drug delivery platform for the treatment of RSV-exacerbated asthma through combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.